英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

surpass    音标拼音: [sɚp'æs]
vt. 超越,凌驾,胜过

超越,淩驾,胜过

surpass
v 1: distinguish oneself; "She excelled in math" [synonym: {excel},
{stand out}, {surpass}]
2: be or do something to a greater degree; "her performance
surpasses that of any other student I know"; "She outdoes all
other athletes"; "This exceeds all my expectations"; "This
car outperforms all others in its class" [synonym: {surpass},
{outstrip}, {outmatch}, {outgo}, {exceed}, {outdo},
{surmount}, {outperform}]
3: move past; "A black limousine passed by when she looked out
the window"; "He passed his professor in the hall"; "One line
of soldiers surpassed the other" [synonym: {travel by}, {pass
by}, {surpass}, {go past}, {go by}, {pass}]
4: be greater in scope or size than some standard; "Their
loyalty exceeds their national bonds" [synonym: {exceed},
{transcend}, {surpass}]

Surpass \Sur*pass"\, v. t. [imp. & p. p. {Surpassed}; p. pr. &
vb. n. {Surpassing}.] [F. surpasser; sur over passer to
pass. See {Sur-}, and {Pass}.]
To go beyond in anything good or bad; to perform (an
activity) better than; to exceed; to excel.
[1913 Webster]

This would surpass
Common revenge and interrupt his joy. --Milton.
[1913 Webster]

Syn: To exceed; excel; outdo; outstrip.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Surpass查看　Surpass　在百度字典中的解释百度英翻中〔查看〕
Surpass查看　Surpass　在Google字典中的解释Google英翻中〔查看〕
Surpass查看　Surpass　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • clinicaltrialresults. org
    SURPASS-CVOT demonstrated that tirzepatide was non-inferior to dulaglutide and superior to a putative placebo on MACE This pre-specified analysis investigated outcomes in patients with and without a prior history of heart failure Median duration of study follow-up=4 years Randomization
  • No Slide Title
    SURPASS CVOT was the first large outcome trial of an incretin-based therapy with an active control arm, showing: Tirzepatide, was noninferior (P<0 001) to the GLP-1 agonist dulaglutide for a 3-component composite of CV death, MI, or stroke Current Analysis
  • Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist . . .
    SURPASS-CVOT is a large phase 3, randomized, double-blind, cardiovascular outcomes trial for tirzepatide assessing both noninferiority and superiority of tirzepatide against dulaglutide (1 5 mg weekly)
  • PowerPoint Presentation
    Tirzepatide demonstrated HbA1c lowering and body weight reduction in the SURPASS trials However, these trials were primarily designed to assess glycemic control, rather than weight management, in people with T2D SURMOUNT-2 was therefore designed to assess the safety and efficacy of tirzepatide for treatment of obesity in T2D
  • Slide 1
    This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist
  • PowerPoint Presentation
    Who are Surpass Assessment Established in 1985, Surpass is an international leader in the provision of computer-based testing technology for secure, high-stakes assessments We provide tailor-made support for any assessment programme with our range of test development services The Surpass platform
  • SURMOUNT-4 Trial results: the impact of tirzepatide on maintenance of . . .
    In this exploratory post hoc analysis of the SURPASS-3 MRI substudy, people with T2D on metformin with without a SGLT-2i treated with tirzepatide showed greater than predicted reduction of muscle fat and as predicted reduction of muscle volume
  • Tirzepatide vs Semaglutide Once weekly in patients with Type 2 Diabetes
    Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
  • The Lancet | The best science for better lives
    Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
  • jnis. bmj. com
    ÐÏ à¡± á; þÿ é þÿÿÿ€ ‚ƒ





中文字典-英文字典  2005-2009